153 results
Page 4 of 8
8-K
EX-99.1
pth 79csbmu8ah9
12 Aug 21
Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
4:18pm
424B3
czk7 b6c39v125poc
21 May 21
Prospectus supplement
4:20pm
8-K/A
EX-99.1
xr44g
17 May 21
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
4:19pm
8-K
EX-99.1
44166x
17 May 21
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
7:31am
8-K
EX-10.1
av9g4kp50v
9 Apr 21
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-99.1
0z26hhjbeqm
11 Mar 21
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
4:23pm
8-K
EX-99.1
43py0femsfmliie1p
10 Mar 21
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for Company’s lead candidate, ADI-001, is believed to be the first IND-cleared allogeneic
7:30am
424B5
wukl1amo
11 Feb 21
Prospectus supplement for primary offering
5:20pm
424B5
xxay2jj0cc27 mkx
10 Feb 21
Prospectus supplement for primary offering
12:00am
8-K
EX-10.1
8muoyudk ok9bp3
5 Jan 21
Entry into a Material Definitive Agreement
4:31pm
424B5
1bcw0ep znl02f3y
1 Dec 20
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
701tr
5 Nov 20
Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update
4:33pm
8-K
EX-99.1
ijg7x4ey
22 Oct 20
Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy
7:15am
424B5
r286ebx1au8y8vs1ql7
21 Sep 20
Prospectus supplement for primary offering
7:58am